• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

What Patients Should Know About Expanded Access Programs

By: StatePoint Media
August 19, 2026 at 01:00 AM EDT
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

photo

SPONSORED CONTENT -- (StatePoint) Expanded Access Programs (EAPs) – sometimes referred to as “compassionate use” – can be a possible path to treatment for some people living with a serious or life-threatening illness.

The American Lung Association with support from Savara, Inc., has launched a campaign to raise awareness about EAPs and chronic lung disease. Here’s what they want you to know:

What are EAPs and who qualifies for them?

EAPs offer access to investigational medical products like drugs or medical devices, when standard treatment options are no longer effective and you cannot participate in a clinical trial, either because you do not qualify or there is not one available to you. In order to be considered for an EAP, you have to meet certain eligibility criteria. You must have a life-threatening or serious illness. Additionally, your licensed physician must also believe the benefits of the investigational treatment outweigh the risks.

Niki, who has been living with a rare chronic lung disease called autoimmune pulmonary alveolar proteinosis (aPAP) for over 20 years, pursued an EAP with the help of her physician. “I don’t have as many options for treatment at this point,” she said.

Expanded Access Programs vs. Clinical Trials

Both EAPs and clinical trials offer experimental treatment and both require certain steps to qualify, but they are not the same. Clinical trials are designed to answer research questions and provide data. EAPs are intended to provide potential treatment options to patients when standard therapies aren’t working and a clinical trial isn’t an option.

While clinical trials have strict eligibility criteria and enrollment limits, expanded access may be available to patients who do not qualify for a trial or who cannot access one.

In Niki’s case, she states, “My physician knew about the clinical trial for this investigational treatment, but I didn’t qualify. When it was offered for expanded access, I knew I wanted to see if I qualified.”

Talking With Your Healthcare Provider is Important

Your licensed physician can help you determine if there is an expanded access treatment available and if it is right for you. They can also help you request approval for it, which requires coordination between them, the treatment manufacturer, an Institutional Review Board and the U.S. Food and Drug Administration.

“I worked closely with my healthcare team to take the steps needed to see if I could receive the treatment. They knew my medical background and helped with the paperwork necessary to apply, so that was very helpful,” says Niki.

For more information about EAPs, visit Lung.org/EAP.

For patients who feel they have run out of options, EAPs may offer another path forward. “This medication gives me hope that there is going to be a treatment to better manage my disease,” says Niki.

Photo Credit: (c) fizkes / iStock via Getty Images Plus

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More
News headline image
Schneider Electric to Acquire PTC for $205 a Share in €21B Industrial Software Deal ↗
Today 14:02 EDT
Via MarketBeat
Topics Artificial Intelligence ETFs
Tickers ADSK PTC
News headline image
NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run ↗
Today 13:50 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers MU NVDA ORCL SKHY TSM
News headline image
A Manufacturing Surprise Could Be a Big Win for These 2 Companies ↗
Today 13:15 EDT
Via MarketBeat
Topics Economy Energy
Tickers EMR ROK
News headline image
BioLife Solutions Shareholders Approve Repligen Merger Agreement ↗
Today 13:02 EDT
Via MarketBeat
Tickers BLFS
News headline image
What a $1 Billion Chip Deal Says About Amazon's AI Ambitions ↗
Today 12:40 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers AMZN GOOGL META MSFT NVDA SNPS

Recent Quotes

View More
Symbol Price Change (%)
AMZN  253.73
+2.21 (0.88%)
AAPL  334.12
+0.43 (0.13%)
AMD  632.73
-1.18 (-0.19%)
BAC  54.24
+0.49 (0.92%)
GOOG  344.79
+4.44 (1.30%)
META  743.70
+15.62 (2.14%)
MSFT  528.64
+11.11 (2.15%)
NVDA  239.73
+5.78 (2.47%)
ORCL  143.66
+1.36 (0.96%)
TSLA  380.97
+10.38 (2.80%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap